Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODYSSEY HIGH FH: Alirocumab in HeFH with High LDL-C
NCT01617655Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 2012
- Primary completion
- May 2014
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in heterozygous familial hypercholesterolemia (HeFH) comparing Alirocumab 150 mg Q2W with Placebo Q2W (2 arms). Primary endpoint: Percent Change From Baseline in Calculated LDL-C at Week 24 - ITT Analysis. Started Jun 2012; status: completed.
02
Drugs
alirocumab
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NCT01617655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01617655.